| Literature DB >> 35638841 |
Wanda M Figueroa-Cuilan1, Matthew Howell1, Christopher Richards1, Amelia Randich1, Akhilesh K Yadav2, Felipe Cava2, Pamela J B Brown1.
Abstract
The remarkable ability of Agrobacterium tumefaciens to transfer DNA to plant cells has allowed the generation of important transgenic crops. One challenge of A. tumefaciens-mediated transformation is eliminating the bacteria after plant transformation to prevent detrimental effects to plants and the release of engineered bacteria to the environment. Here, we use a reverse-genetics approach to identify genes involved in ampicillin resistance, with the goal of utilizing these antibiotic-sensitive strains for plant transformations. We show that treating A. tumefaciens C58 with ampicillin led to increased β-lactamase production, a response dependent on the broad-spectrum β-lactamase AmpC and its transcription factor, AmpR. Loss of the putative ampD orthologue atu2113 led to constitutive production of AmpC-dependent β-lactamase activity and ampicillin resistance. Finally, one cell wall remodeling enzyme, MltB3, was necessary for the AmpC-dependent β-lactamase activity, and its loss elicited ampicillin and carbenicillin sensitivity in the A. tumefaciens C58 and GV3101 strains. Furthermore, GV3101 ΔmltB3 transforms plants with efficiency comparable to that of the wild type but can be cleared with sublethal concentrations of ampicillin. The functional characterization of the genes involved in the inducible ampicillin resistance pathway of A. tumefaciens constitutes a major step forward in efforts to reduce the intrinsic antibiotic resistance of this bacterium. IMPORTANCE Agrobacterium tumefaciens, a significant biotechnological tool for production of transgenic plant lines, is highly resistant to a wide variety of antibiotics, posing challenges for various applications. One challenge is the efficient elimination of A. tumefaciens from transformed plant tissue without using levels of antibiotics that are toxic to the plants. Here, we present the functional characterization of genes involved in β-lactam resistance in A. tumefaciens. Knowledge about proteins that promote or inhibit β-lactam resistance will enable the development of strains to improve the efficiency of Agrobacterium-mediated plant genetic transformations. Effective removal of Agrobacterium from transformed plant tissue has the potential to maximize crop yield and food production, improving the outlook for global food security.Entities:
Keywords: Agrobacterium tumefaciens; ampicillin; anhydro amidases; antibiotic resistance; membrane-bound lytic transglycosylases; plant transformation; β-lactamases
Mesh:
Substances:
Year: 2022 PMID: 35638841 PMCID: PMC9238390 DOI: 10.1128/aem.00333-22
Source DB: PubMed Journal: Appl Environ Microbiol ISSN: 0099-2240 Impact factor: 5.005
FIG 1The AmpC-AmpR operon is responsible for induced ampicillin resistance in Agrobacterium tumefaciens C58. (A) Operon organization and proposed ampicillin resistance mechanism. (Left, No AMP) Briefly, in the absence of β-lactams such as ampicillin (AMP), ampC expression is repressed by AmpR. AmpR-mediated repression is maintained as long as the AmpR-inactivating ligand, UDP-GM-pentapeptide, is bound to AmpR (PampC OFF). (Right, +AMP) In contrast, the presence of ampicillin (AMP) increases the pools of AmpR-activating ligands or the cell wall degradation fragments (anhydro modification is depicted by a ring), which are known to displace AmpR-inactivating ligands. As a result, the increase in AmpR-activating ligands activates AmpR and ampC is transcribed (PampC ON). (B) Growth of A. tumefaciens WT, ΔampC, and ΔampR cells in the absence (No AMP) and presence of ampicillin at 25 or 50 μg/mL (AMP 25 or AMP 50, respectively) for 24 h (n = 1; 2 replicates). (C) Quantitative analysis of phase-contrast microscopy of exponentially growing strains in the absence (No AMP) or presence of ampicillin at 25 μg/mL (AMP 25). The percent phenotype was calculated by counting the number of cells displaying one of the phenotypes indicated (1 cell = 1 phenotype) and dividing it by the total number of cells per strain. (D) Ampicillin susceptibility assay performed by spotting dilutions. Briefly, exponential cultures were serially diluted, spotted on LB solid medium containing no ampicillin (No AMP) or ampicillin at 25 μg/mL (AMP 25), and incubated at 28°C for 36 h before imaging. Plates used to demonstrate complementation (ΔampC + pAmpC or ΔampR + pAmpR) included 1 μM IPTG to induce expression of plasmid-encoded AmpC or AmpR. (E) Disk susceptibility was performed on lawns of the indicated strains grown on LB plates for 24 h at 28°C (n = 2). AMP 10, disk containing 10 μg/mL of ampicillin; AMP 10/SUL 10, disk containing 10 μg/mL of ampicillin and 10 μg/mL of sulbactam, a broad-spectrum β-lactamase inhibitor. Data represent the mean (±standard deviation [SD]) of three independent experiments. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.1; ns, not significant. (F) Determination of β-lactamase production performed by a nitrocefin assay using cell lysates. No AMP or AMP 25 indicates cells untreated or treated with ampicillin at 25 μg/mL, respectively, for 2 h before the generation of cell lysates. The data shown represent one of two biological replicates.
FIG 2Loss of AmpD results in constitutive β-lactamase activity and elevated ampicillin resistance. (A) Ampicillin susceptibility assay performed by spotting dilutions. Briefly, exponential cultures were serially diluted and spotted on solid medium containing no ampicillin (No AMP) or ampicillin at 25, 100, or 160 μg/mL (AMP 25, AMP 100, or AMP 160, respectively) and incubated at 28°C for ~40 h before imaging. Plates used to demonstrate complementation of ΔampD (ΔampD + pAmpD) included 1 μM IPTG to induce expression of plasmid-encoded AmpD. (B) Growth of A. tumefaciens WT and ΔampD in the absence (No AMP) and presence of various concentrations of ampicillin (AMP 25 or AMP 100) for 24 h (n = 1; 2 replicates). (C) Quantitative analysis of phase-contrast microscopy of exponentially growing strains treated with ampicillin at 25 μg/mL (AMP 25). The percent phenotype was calculated by counting the number of cells displaying one of the indicated phenotypes (1 cell = 1 phenotype) and dividing it by the total number of cells for each strain. (D) Disk susceptibility assay performed on a lawn of indicated strains grown on LB plates for 24 h at 28°C. AMP 10, disk containing 10 μg/mL ampicillin; AMP 10/SUL 10, disk containing 10 μg/mL ampicillin and 10 μg/mL sulbactam, a broad-spectrum β-lactamase inhibitor. Data represent the mean (±SD) of three independent experiments. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.1; ns, not significant.
FIG 3AmpC is the β-lactamase that confers ΔampD cells elevated ampicillin resistance. (A) An ampicillin susceptibility assay was performed by spotting dilutions. Briefly, exponentially grown cultures were serially diluted, spotted on solid medium containing no ampicillin (No AMP) or ampicillin at 25 μg/mL (AMP 25), and incubated at 28°C for ~40 h before imaging. (B) Quantitative analysis of phase-contrast microscopy of exponentially growing strains untreated (No AMP) or treated with ampicillin at 25 μg/mL (AMP 25). The percent phenotype was calculated by counting the number of cells displaying one of the indicated phenotypes (1 cell = 1 phenotype) and dividing it by the total number of cells for each strain. (C) Determination of β-lactamase production was performed by a nitrocefin assay using cell lysates. No AMP or AMP 25 indicates cells untreated or treated with ampicillin at 25 μg/mL, respectively, for 2 h before the generation of cell lysates. Data represent one of two biological replicates.
FIG 4MtlB3 is required for ampicillin resistance in A. tumefaciens. (A) Phase-contrast microscopy of exponentially growing strains treated with ampicillin at 25 μg/mL (AMP 25) for 2 h. (B) Quantitative analysis of phase-contrast microscopy of exponentially growing strains treated with ampicillin at 25 μg/mL (AMP 25) for 2 h. The percent phenotype was calculated by counting the number of cells displaying one of the phenotypes indicated (1 cell = 1 phenotype) and dividing it by the total number of cells for each strain. (C) Growth of A. tumefaciens WT and ΔmltB3 in the absence (No AMP) and presence of ampicillin at 25 μg/mL (AMP 25) for 24 h (n = 1; 2 replicates). (D) Determination of β-lactamase production was performed by a nitrocefin assay using cell lysates. No AMP or AMP 25 indicates cells untreated or treated with ampicillin at 25 μg/mL, respectively, for 2 h before the generation of cell lysates. Data shown represent one of two biological replicates.
FIG 5A. tumefaciens GV3103 ΔmltB3 can be used to transform plants efficiently, and bacteria can be removed using low concentrations of ampicillin. (A) An ampicillin susceptibility assay was performed by spotting dilutions. Briefly, exponentially grown cultures were serially diluted, spotted on solid medium containing no ampicillin (No AMP), ampicillin at 25 μg/mL (AMP 25), or carbenicillin at 15 μg/mL (CARB 15), and incubated at 28°C for ~40 h before imaging. (B) Determination of β-lactamase production was performed by a nitrocefin assay using cell lysates. Data shown represent one of two biological replicates. No AMP or AMP 25 indicates cells untreated or treated with ampicillin at 25 μg/mL, respectively, for 2 h before the generation of cell lysates. (C and D) Transformation efficiency (C) and bacterial loads (D) of seeds transformed with WT A. tumefaciens GV3101 and GV3101 ΔmltB3 using the floral dip assay technique (83).
FIG 6Working model for A. tumefaciens ampicillin resistance. Bifunctional PBPs extend the cell wall through the transglycosylation (linking of carbohydrates) and transpeptidation (linking of peptide stems) reactions using cytoplasmic precursors (step 1). β-Lactams such as ampicillin (purple stars) target the transpeptidase domain of penicillin-binding proteins (PBPs) (step 2), leading to a block in bacterial cell growth and increased hydrolytic activity by lytic transglycosylases. In A. tumefaciens, inactivation of the lytic transglycosylase MltB3 results in inhibition of β-lactamase derepression and lysis, suggesting that MltB3 is likely required for the generation of cell wall degradation products (step 3) that are transported to the cytoplasm (step 4). In the cytoplasm, hydrolytic enzymes (steps 5 to 7) digest cell wall degradation products and promote PG recycling, enabling de novo PG synthesis (step 8). Similar to treatment with β-lactams, where a block in cell growth leads to an increase in cell wall degradation products (Anh-Mur), inactivation of anhydro amidases such as AmpD (step 6) increases the pool of cell wall degradation products, leading to β-lactam resistance. In A. tumefaciens, inactivation of AmpD leads to derepression of β-lactamases and ampicillin resistance (step 9). Both AmpC, an inducible β-lactamase that is under the transcriptional control of AmpR, and AmpR seem to be responsible for the derepression observed in ΔampD cells. Thus, our working model suggests that upon ampicillin exposure, a block in growth leads to increased activity of MltB3. An increase in cell wall degradation products leads to induction of AmpC expression by AmpR and the presumed translocation of AmpC to the periplasm, resulting in ampicillin resistance.
Strains and plasmids used in this study
| Strain or plasmid | Relevant characteristics | Reference/source |
|---|---|---|
| Source plasmids | ||
| pSRKKm-Plac-sf | pSRKKm vector containing | ( |
| pNTPS139 | Kmr; suicide vector containing | D. Alley |
| Deletion plasmids | ||
| pNTPS139 Δ | Kmr Sucs; deletion plasmid for | This study |
| pNTPS139 Δ | Kmr Sucs; deletion plasmid for | This study |
| pNTPS139 Δ | Kmr Sucs; deletion plasmid for | This study |
| pNTPS139 Δ | Kmr Sucs; deletion plasmid for | This study |
| pNTPS139 Δ | Kmr Sucs; deletion plasmid for | This study |
| pNTPS139 Δ | Kmr Sucs; deletion plasmid for | This study |
| pNTPS139 Δ | Kmr Sucs; deletion plasmid for | This study |
| pNTPS139 Δ | Kmr Sucs; deletion plasmid for | This study |
| pNTPS139 Δ | Kmr Sucs; deletion plasmid for | This study |
| pNTPS139 Δ | Kmr Sucs; deletion plasmid for | This study |
| pNTPS139 Δ | Kmr Sucs; deletion plasmid for | This study |
| Replicating plasmid | ||
| Plac- | Kmr; pSRKKm vector containing | This study |
| Plac- | Kmr; pSRKKm vector containing | This study |
| Plac- | Kmr; pSRKKm vector containing | This study |
| Plac- | Kmr; pSRKKm vector containing | This study |
| Strains | ||
| | ||
| DH5α | Cloning strain | Life Technologies |
| S17.1 | Smr; RP4-2, Tc::Mu,Km-Tn | ( |
| | ||
| C58 | Nopaline type strain; pTiC58; pAtC58 | |
| GV3101 | C58-derived; pTiC58DT-DNA; strain for | John Walker lab |
| FC2452 | Deletion strain for Δ | This study |
| FC2444 | Deletion strain for Δ | This study |
| FC2465 | Deletion strain for Δ | This study |
| FC2487 | Deletion strain for Δ | This study |
| FC2446 | Deletion strain for Δ | This study |
| FC2448 | Deletion strain for Δ | This study |
| FC2450 | Deletion strain for Δ | This study |
| C58 Δ | Replacement of the Δ | ( |
| C58 Δ | Deletion strain for Δ | This study |
| C58 Δ | Kmr; deletion of | This study |
| C58 Δ | Deletion strain for Δ | This study |
| C58 Δ | Kmr; deletion of | This study |
| C58 Δ | Deletion strain for Δ | This study |
| C58 Δ | Kmr; deletion of | This study |
| C58 Δ | Deletion strain for Δ | This study |
| C58 Δ | Deletion strain for Δ | This study |
| C58 Δ | Deletion strain for Δ | This study |
| C58 GV3101 Δ | Deletion strain for Δ | This study |
Synthesized DNA primers used in this study
| Synthesized DNA | Sequence |
|---|---|
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- | |
| 5′- |
Fwd, forward; Rvs, reverse.